FREIBURG, Germany and ROSCREA, Ireland, April 16, 2026, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced that data from the Global Phase 2b MOVE-IT study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis has been selected for a late-breaking oral presentation at DDW 2026 in Chicago, USA, May 2-5.

Late-Breaker Presentation Details
Title: Naronapride in Idiopathic and Diabetic Gastroparesis: Results from a Phase 2b Randomized Control Trial
Presenter: Tack, Jan F
Session Title: Gastric Motility, Gastroparesis, Nausea and Vomiting 
Session Date and Time: Sunday, May 3, 2026 from 2:00 PM to 3:30 PM CDT 

About Naronapride 
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract.  Naronapride works through a differentiated dual mechanism of action- 5-HT4 receptor agonism and dopamine D2 receptor antagonism- modulating two validated targets on the luminal surface of the intestinal wall that regulate GI motility and nausea signaling. Naronapride’s dual mechanism of action, minimal systemic bioavailability, and differentiated pharmaceutical and pharmacokinetic profile are designed to deliver targeted activity within the GI tract while limiting systemic exposure.  To date, naronapride has demonstrated a favorable safety and tolerability profile across nine Phase 1 clinical trials and five Phase 2 clinical trials conducted in multiple indications including gastroesophageal reflux disease, erosive esophagitis and chronic idiopathic constipation.

About Gastroparesis
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying and debilitating symptoms including nausea, vomiting, early satiety, upper abdominal pain and postprandial fullness. Approximately 22 per 100,000 individuals across US and Europe are formally diagnosed with gastroparesis, while up to 12-times more experience symptoms consistent with the disease. Despite the substantial disease burden, the availability of safe and effective long‑term treatment options remains limited.

About Renexxion 
Renexxion Ireland Limited is a wholly owned Irish subsidiary of California-based Renexxion, Inc. Renexxion is a privately held biopharmaceutical company committed to developing new therapies for patients with gastrointestinal disorders. Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract. 
Further information on Renexxion can be found online: https://www.rnexltd.ie